No black box warning on record for Dihydroergotamine Mesylate Nasal

As of the latest FDA labeling reviewed, Dihydroergotamine Mesylate Nasal (DIHYDROERGOTAMINE MESYLATE NASAL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dihydroergotamine Mesylate Nasal medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Dihydroergotamine mesylate nasal spray should only be used where a clear diagnosis of migraine headache has been established. CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide anti

No black box warning on record for Dihydroergotamine Mesylate Nasal

Other warnings & precautions

WARNINGS Dihydroergotamine mesylate nasal spray should only be used where a clear diagnosis of migraine headache has been established. CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide anti

Dihydroergotamine Mesylate Nasal Black Box Warning

No black box warning on record for Dihydroergotamine Mesylate Nasal

Other warnings & precautions

Dihydroergotamine Mesylate Nasal Black Box Warning

No black box warning on record for Dihydroergotamine Mesylate Nasal

Other warnings & precautions